| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/08/2004 | WO2004056209A1 Ginseng-containing agent for producing a sensation of satiety and for weight reduction |
| 07/08/2004 | WO2004045572A8 Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil |
| 07/08/2004 | WO2004043435A3 Systemic delivery of antiviral agents |
| 07/08/2004 | WO2004043432A3 Controlled release depot formulations |
| 07/08/2004 | WO2004043393A3 Compositions for diabetes treatment and prophylaxis |
| 07/08/2004 | WO2004039351A3 Pharmaceutical compositions suitable for the treatment of ophthalmic diseases |
| 07/08/2004 | WO2004037226A3 Pharmaceutical compositions containing venlafaxine |
| 07/08/2004 | WO2004037184A3 Methods for the treatment of skin disorders |
| 07/08/2004 | WO2004035022A3 Prepolymeric materials for site specific delivery to the body |
| 07/08/2004 | WO2004026257A3 Treatment of irritable bowel syndrome and related bowel diseases |
| 07/08/2004 | WO2004024209A3 Materials and methods for drug delivery and uptake |
| 07/08/2004 | WO2004024128A3 Modified release ketoprofen dosage form |
| 07/08/2004 | WO2004024121A3 Methods of measuring the dissolution rates of an analyte in a non-aqueous liquid composition |
| 07/08/2004 | WO2004019909A3 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 07/08/2004 | WO2004014322A3 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 07/08/2004 | WO2004012653A3 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 07/08/2004 | WO2004004654A3 Vaccines to induce mucosal immunity |
| 07/08/2004 | WO2003099213A3 Method for reducing platelet count |
| 07/08/2004 | WO2003092625A3 Carvedilol formulations |
| 07/08/2004 | WO2003074033A8 Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
| 07/08/2004 | WO2003059193A8 Use of nanoparticles as carriers for biocides in ophthalmic compositions |
| 07/08/2004 | WO2003057187A8 Combinations of viscoelastics for use during surgery |
| 07/08/2004 | WO2003053292B1 Vaginal delivery of drugs |
| 07/08/2004 | WO2003039553B1 Compositions for treatment of postmenopausal female sexual dysfunction |
| 07/08/2004 | WO2003020245A8 Residual solvent extraction method and microparticles produced thereby |
| 07/08/2004 | US20040133188 Medical equipment comprising enclosures for holding cells and oxygen generators for oxygenation of the cells; grafting |
| 07/08/2004 | US20040133187 Methods and systems for providing orthogonally redundant monitoring in a sedation and analgesia system |
| 07/08/2004 | US20040133186 Programmed pulsed infusion methods and devices |
| 07/08/2004 | US20040133155 Devices for intraocular drug delivery |
| 07/08/2004 | US20040133099 Diagnosis or prophylaxis of ear disorders comprising transporting nanostructure particles conjugated with lipids, proteins, animal growth regulators, hormones, antioxidants, free radical scavengers, steroids or drugs, into ears |
| 07/08/2004 | US20040132989 Enhancing purity of lactose via demineralization and alcohol precipitation; infant dairy product; veterinary medicine |
| 07/08/2004 | US20040132988 Immunoeffector compounds |
| 07/08/2004 | US20040132827 Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions |
| 07/08/2004 | US20040132826 Modified release compositions of milnacipran |
| 07/08/2004 | US20040132823 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| 07/08/2004 | US20040132815 sulfodehydroabietic acid or a salt thereof; may be administered as a gargle, a liniment, a patch, a spray, a troche or a buccal preparation. |
| 07/08/2004 | US20040132814 Pharmaceutical compositions |
| 07/08/2004 | US20040132808 precipitating the citalopram base in crystalline form, and transforming the base into a pharmaceutically acceptable citalopram salt; useful for removing intermediates which are structurally closely related to citalopram |
| 07/08/2004 | US20040132806 polymeric coating with a pH-independent dissolution profile that inhibits the release of the pravastatin in the stomach, and permits release in the intestine; side effect reduction |
| 07/08/2004 | US20040132802 delaying release of a poorly water soluble statin, especially simvastatin and/or lovastatin, for a time sufficient to avoid exposure of said statin to the stomach, duodenum, and jejunum; and releasing said statin in the ileum, colon, or both |
| 07/08/2004 | US20040132798 containing a benzonitrile group and N-substituted with a tert-butylcarbonylmethyl- or a tert-butyloxycarbonylaminoethyl- group; particularly in a gelling polymer matrix to form modified release composition |
| 07/08/2004 | US20040132771 solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor resulting in improved bioavailability |
| 07/08/2004 | US20040132761 water or a water/ethanol mixture as solvent; acid for achieving a pH of 2.0-4.5; and a preservative; optionally including a complexing agent, stabilizer, a pharmacologically acceptable cosolvent, and other adjuvants and additives |
| 07/08/2004 | US20040132756 incorporating tartaric acid in a solid preparation having a high content of a quinolone compound, particularly sitafloxacin; reduced in fluctuations of oral absorption |
| 07/08/2004 | US20040132739 e.g. RO 28-2653 in combination with Cisplatin, Paclitaxel, Gemcitabine or Etoposide; treating patients with solid metastasized or non-metastasized tumors |
| 07/08/2004 | US20040132722 Glycoprotein-mediated MDR |
| 07/08/2004 | US20040132712 Together with one or more pharmaceutically active ingredients, e.g. antibiotics, to prevent or reduce rapid degradation of the active ingredient by bacteria |
| 07/08/2004 | US20040132704 Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| 07/08/2004 | US20040132702 luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects |
| 07/08/2004 | US20040132700 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial madrix adhesion such as asthma cystic fibrosis and influenza |
| 07/08/2004 | US20040132692 A freeze drying mixture comprising an epothilone and a cyclodextrin; antiproliferative agent, anticarcinogenic agent; cancer, psoriasis, restenosis, multiple sclerosis, rheumatoid arthritis, atherosclerosis; side effect reduction |
| 07/08/2004 | US20040132690 Gel based on chitosan and lactic acid; acidity; dosage form suppository or vaginal tablet; prevention and treatment of vaginal Infections, restoring the physiological lactobacilli flora |
| 07/08/2004 | US20040132685 Immunostimulatory nucleic acid |
| 07/08/2004 | US20040132683 Expression of exogenous polynucleotide sequences in a vertebrate |
| 07/08/2004 | US20040132676 Polynucleotide formulation for enhanced intracellular transfer |
| 07/08/2004 | US20040132670 Method of production of an isomaltulose-containing enteral nutrient |
| 07/08/2004 | US20040132666 Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| 07/08/2004 | US20040132656 Blood-coagulation factor VIII (or antihemophilic factor) containing trehalose stabilizer in absence of albumin; reconstitution with water |
| 07/08/2004 | US20040132653 Lyophilized composition of bone morphogenetic factor human MP52 |
| 07/08/2004 | US20040132143 using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure with a targeted size |
| 07/08/2004 | US20040131771 Coating of particulate material with organic based coating composition for the preparation of drug delivery systems |
| 07/08/2004 | US20040131733 solubilisation of lycopene in this supercritical fluid and to separate the lycopene concentrate by depressurisation carried out at pressures below 10 MPa to produce an oleoresin |
| 07/08/2004 | US20040131706 Pharmaceutical preparation |
| 07/08/2004 | US20040131698 Methods of treating conditions using metal-containing materials |
| 07/08/2004 | US20040131696 Administering aluminum compound complexed to polyoxyalkylene glycol |
| 07/08/2004 | US20040131693 Topical applying |
| 07/08/2004 | US20040131692 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
| 07/08/2004 | US20040131691 Forming oil in water emulsion in presence of surfactants; heating, cooling; encapsulation oil drops |
| 07/08/2004 | US20040131689 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor |
| 07/08/2004 | US20040131688 Mixture of biological tissue, particles and confining liquid; stability; three-dimensional; absorption, decomposition of toxicity ; encapsulation of bacteria |
| 07/08/2004 | US20040131687 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 07/08/2004 | US20040131686 Composition and method for treatment of bacterial vaginal infections |
| 07/08/2004 | US20040131685 Sustained release mixture; respiratory system disorders; antiallergens |
| 07/08/2004 | US20040131684 Omeprazole formulation |
| 07/08/2004 | US20040131683 Compositions for conjugated estrogens and associated methods |
| 07/08/2004 | US20040131682 Pulsatile release histamine H2 antagonist dosage form |
| 07/08/2004 | US20040131681 Antibiotic microspheres for treatment of infections and osteomyelitis |
| 07/08/2004 | US20040131680 Side effect reduction |
| 07/08/2004 | US20040131679 Process for producing an oral sustained-release preparation of fasudil hydrochloride |
| 07/08/2004 | US20040131678 Resorbable bone cement containing active agents |
| 07/08/2004 | US20040131677 Absorption; side effect reduction; encapsulation in polyvinylpyrrolidone; bioavailability |
| 07/08/2004 | US20040131676 Dosage forms containing a PPI, NSAID, and buffer |
| 07/08/2004 | US20040131675 Coated grains of active materials; heat and acid resistance; proton pump inhibitor |
| 07/08/2004 | US20040131674 Gastric acid secretion inhibiting composition |
| 07/08/2004 | US20040131673 Manufacturing dissolvable dosage forms |
| 07/08/2004 | US20040131672 Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties |
| 07/08/2004 | US20040131671 Sustained release formulations containing acetaminophen and tramadol |
| 07/08/2004 | US20040131670 Pellicle-resistant gelatin capsule |
| 07/08/2004 | US20040131669 Drug in coated capsule; granulation of active materials |
| 07/08/2004 | US20040131668 Two-part capsule to accept pharmaceutical preparations for powder inhalers |
| 07/08/2004 | US20040131667 Liposomal analgesic formulation and use |
| 07/08/2004 | US20040131666 Liposome encapsulating active materials |
| 07/08/2004 | US20040131665 Topical anesthetic formulation |
| 07/08/2004 | US20040131664 Topical stabilized prostaglandin E compound dosage forms |
| 07/08/2004 | US20040131662 Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
| 07/08/2004 | US20040131661 High speed dissolving; low viscosity; casting pullulan and alginates |
| 07/08/2004 | US20040131660 Porous or absorbent sheet, wipe impregnated with oil in water emulsions |
| 07/08/2004 | US20040131655 Ophthalmic drug delivery device |
| 07/08/2004 | US20040131654 Active drug in shape for insertion into eye; sustained release |
| 07/08/2004 | US20040131653 Vasodilator impregnated devices and methods |